Biofrontera Inc. (BFRI) 12-Month Stock Forecast & Price Target Cone

Per the Roarable RQD rating, BFRI scores 27 out of 100 with a letter grade of E, labeled "Roarable Strong Sell — Forensic Risk / Avoid." The five pillars are: Fundamental Cash Engine at 4/20 (ROIC -35%; FCF yield 0%); Whale 13F Flow at 6/20 (institutional accumulation and options positioning); Insider Conviction at 3/20 (SEC Form 4 and Congressional PTR cluster flow); Macro Regime Fit at 6/20 (Beta 1.0; sector sensitivity); and Forensic Balance Sheet at 8/20 (Altman Z 2.5; Piotroski F 3/9; Debt/Equity 0.5).

Taken together, the lowest-scoring pillars sit on the cash-generation and insider-signal sides. A 0% FCF yield and -35% ROIC mean the reported financials do not currently show the business converting capital into cash returns, and the insider pillar's low score means the source data contains little supportive insider behavior. The balance sheet pillar is the highest-scoring of the five, but at 8/20 it is still weak, with a Piotroski F-Score of 3/9. For a prospective investor, the upside case rests on operating improvement or external catalysts rather than on current cash generation or insider conviction. The valuation tradeoff is that a $0.93 price with a $13.8M market cap is priced against negative returns, so any thesis depends on a turnaround the source data does not yet demonstrate.

Biofrontera Inc. (BFRI) is listed on NASDAQ and classified under the Health Care sector, within the Biotechnology: Pharmaceutical Preparations industry, per the company profile. Per the SEC financials, the company reported revenue of $41.7M for FY 2025. The source data does not describe its products, customers, or revenue model beyond these classifications.

Per the SEC financials, revenue grew from $34.1M (FY 2023) to $41.7M (FY 2025), while net losses narrowed from $-20.1M to $-10.5M over the same span. Market data reports an operating margin of -27.2%, a net margin of -25.3%, a gross margin of 0%, and ROIC of -35%. The Altman Z-Score is 2.5 and the Piotroski F-Score is 3/9, both per the Roarable RQD rating's forensic balance sheet pillar. Debt/Equity is 0.5 per the same source, while reported debt figures in the financial table are not available in source data.

Per the recent news feed, the headlines include a Nasdaq notice regarding listing and/or registration removal for BFRI warrants, a Supplemental New Drug Application submission by Biofrontera, and several market-movement reports listing BFRI among pre-market or after-market movers. The warrant listing notice is the most direct risk item in the feed. The Supplemental New Drug Application submission is the most direct potential catalyst. The remaining items are third-party market-action reports without stated fundamental content. Per the Butterfly Supply-Chain Graph, the supply chain is recorded as NONE, with no butterfly links and no proprietary signals.

• What is the nature and timing of the Supplemental New Drug Application, and what product does it concern?
• What are the reasons and implications of the Nasdaq notice regarding warrant listing or registration removal?
• What are the reported debt levels, since the financial table lists debt as N/A?
• What drove the FY 2025 revenue growth to $41.7M, and what is the path to positive cash flow given FY 2025 FCF of $-13.4M?
• What explains the gap between the market-data Beta of 1.0 and the 52-week range of $0.56 to $1.66 relative to the current $0.93 price?